Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03777657
Title Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | POL | ITA | GBR | FRA | ESP


No variant requirements are available.